Pharmacy Times
JUNE 11, 2025
Completion Date (Estimated): June 2027 “For people living with advanced ROS1+ lung cancer, who tend to be diagnosed at a younger age, having another treatment option can make a real difference for them and their loved ones,” Janet Freeman-Daily, cofounder and president of The ROS1ders, said in a news release.
Pharmaceutical Technology
JULY 1, 2025
Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Sign up for our daily news round-up!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
JULY 23, 2025
ADCs continue to possess the potential to provide a more impactful benefit to patients than chemotherapy alone, with a more limited toxicity profile. All patients in the study had progressed following platinum-based chemotherapy, and 90% of patients had progressed after immune checkpoint inhibitors. and 30% from China. mg/kg, 1.2
European Pharmaceutical Review
MAY 4, 2023
Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Global Bispecific Antibodies for Cancer Market 2023-2027. Personalized medicine at FDA. Internet] Personalized Medicine Coalition. cited 2023Apr. Available from: [link] 8.
The Happy PharmD
SEPTEMBER 4, 2024
Did you know that the infusion pharmacy market is projected to reach $20 billion dollars by 2027? From chemotherapy to nutrition support and infectious disease treatments, infusion pharmacists play a vital role in delivering specialized care directly to patients. Many pharmacists wonder how this growth could impact their careers.
Roots Analysis
OCTOBER 4, 2023
One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy. during the period 2023-2035. during the period 2023-2035. during the period 2023-2035.
Blog: Ask a Student Pharmacist
JUNE 21, 2023
Particularly, we devote a large portion of our research to identifying novel compounds that impact cellular uptake or inhibit drug efflux - the most common mechanism underlying acquired drug resistance in cancer, pinpointing the transporters or targets involved in these processes, and evaluating regimens to produce desirable anti-cancer responses.
Expert insights. Personalized for you.
Let's personalize your content